Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:30:36 2026-05-15 am EDT			5-day change	1st Jan Change
116.68 ^CHF	-0.10%		+2.93%	+6.46%

May. 15	Health Rounds: Common ADHD medicines help treat cancer-related fatigue	RE
May. 13	Wall Street Just Got Its Wholesale Receipt

NOVARTIS AG : UBS reiterates its Neutral rating

Published on 04/10/2026 at 02:16 am EDT

MarketScreener with dpa-AFX Analyser

NOVARTIS AG

-0.10%

In a research note, UBS analyst Matthew Weston has maintained his recommendation on the stock with a Neutral rating. The target price is unchanged at CHF 116.

Latest news about Novartis AG

May. 15	Health Rounds: Common ADHD medicines help treat cancer-related fatigue	RE
May. 13	Wall Street Just Got Its Wholesale Receipt
May. 13	Inflation weighs on the mood
May. 11	Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence	DJ
May. 08	A lot of noise, little impact?
May. 08	Much ado about nothing?
May. 07	Novartis Starts Construction on Texas Cancer Therapy Manufacturing Facility	MT
May. 07	Novartis AG - Denton site expected to be operational in 2028 and create new US jobs	RE
May. 07	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	DJ
May. 07	Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities	DJ
May. 07	Novartis Breaks Ground on Denton, Texas Radioligand Therapy Site Construction Now Underway Across All New Us Facilities	CI
May. 06	Bayer's experimental blood thinner cuts risk and severity of repeat strokes	RE
May. 06	Novo Nordisk weight-loss pill powers profit beat in race to catch Eli Lilly	RE
May. 05	Novartis to Close Manufacturing Plant in Wehr, Germany	MT
May. 05	Novartis to cut 220 jobs as it closes German site	RE

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - oncology (30.9%); - immunology (18.9%); - cardiovascular, renal and metabolic diseases (16.4%); - neuroscience (11%). The remaining net sales (22.8%) are from contract manufacturing of pharmaceutical products. At the end of 2025, Novartis AG had over 31 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (2.6%), Europe (28.1%), the United States (42.8%), Asia/Africa/Australasia (19.8%), Canada and Latin America (6.7%).

Employees

75,267

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company